Previous 10 | Next 10 |
NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs...
2023-07-27 17:34:32 ET There’s something special about penny stocks . Even when the stock market is down, like it is today, you’re likely to find at least a handful exploding higher. Obviously, there’s plenty of risk that comes along with trading cheap stocks. But t...
NEW YORK and LONDON, July 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European Commission granted orphan drug designation to nomacopan as a ...
NEW YORK and LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences executive Wendy DiCicco as interim...
Akari is on track for start of enrollment by the end of 2023 in the registrational Phase 3 study of nomacopan in pediatric HSCT-TMA Akari is moving forward into a Phase 3 double-blind placebo-controlled clinical trial of nomacopan in adult HSCT-TMA and will begin enrollment in 2024 NE...
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials for treatment of geographic atrophy (GA) The company remains on track for an IND submission in the first half of 2024 and the start of clinical tria...
NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the c...
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of industry veteran Wa’el Hashad to the Akari Board of D...
2023-06-23 15:22:26 ET As the end of the second quarter draws near, a range of notable companies are set to release their earnings reports next week. Leading the pack is Nike ( NYSE: NKE ), the footwear and sports apparel giant. Elsewhere, chip makers Micron Technology ( NASDA...
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has appointed Torsten Hombeck, Ph.D...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...